PET-CT imaging in a rare metabolic myopathy pediatric case

doi:10.15406/ijrrt.2017.02.00039

International Journal of

eISSN: 2574-8084

Radiology & Radiation Therapy

Short Communication Volume 2 Issue 5

PET-CT imaging in a rare metabolic myopathy pediatric case

Pelin Ozcan Kara,¹

Verify Captcha

Regret for the inconvenience: we are taking measures to prevent fraudulent form submissions by extractors and page crawlers. Please type the correct Captcha word to see email ID.

Zehra Pinar Koc,¹ Cetin Okuyaz,² Elvan Caglar Citak,³ Ali Ertug Arslankoylu,⁴ Suzan Zorludemir,⁵ Ozlem Tezol²

¹Department of Nuclear Medicine, Mersin University, Turkey
²Department of Pediatric Neurology, Mersin University, Turkey
³Department of Pediatric Oncology, Mersin University, Turkey
⁴Department of Pediatric Intensive Care, Mersin University, Turkey
⁵Department of Pathology, Cukurova University, Turkey

Correspondence: Pelin Ozcan Kara, Mersin University Hospital, Department of Nuclear Medicine, 33343 Mersin, Turkey, Tel -805540593

Received: April 02, 2017 | Published: April 5, 2017

Citation: Kara PO, Koc ZP, Okuyaz C, et al. PET-CT imaging in a rare metabolic myopathy pediatric case. Int J Radiol Radiat Ther. 2017;2(5):129-130. DOI: 10.15406/ijrrt.2017.02.00039

Download PDF

Abstract

F18 - Fluorodeoxyglucose (FDG) PET/CT have found widespread application area especially in oncological patients. In the present case, diagnosis of metabolic myopathy detected on FDG PET-CT imaging performed for investigation of malignancy in a child patient with paraneoplastic syndrome was presented. Rare pediatric metabolic myopathy case FDG PET-CT findings was demonstrated for the first time in the literature.

Keywords: metabolic myopathy, PET-CT, FDG

Abbreviations

FDG, fluorodeoxyglucose; CT, computed tomography; MRI, magnetic resonance ımaging; PET-CT, positron emission tomography–computed tomography

Short communication

Thirteen-year-old female patient with normal cerebral and muscular magnetic resonance imaging (MRI) was referred to our department for PET/CT imaging on examination of underlying malignancy. She had weight loss, widespread pain, unexplained LDH and uric acid level. Postbrandial state was ruled out and following fasting for 4hours i.v. 5.2mCi 18F-FDG was injected. Sixty minutes later images to be 2-3minutes per bed in 3D mode were taken from the calvarium to the footpad. Images taken on GE Discovery PET/CT 610 (General Electric Medical Systems, Milwaukee, WI,USA) were evaluated after attenuation correction with low-dose CT. PET/CT imaging demonstrated symmetrical diffuse markedly increased metabolic activity (SUVmax: 5.74-12.66) including all the cross-sectional area in skeletal muscle structure. Except this, no additional finding or FDG avid malignancy was found. According to the PET-CT findings, inflammatory muscle diseases was considered and muscle biopsy was suggested. Biopsy confirmed the diagnosis of metabolic myopathy. FDG PET-CT imaging is a standard whole body imaging modalitie with widespread use in the field of oncology. However, there are limited number of articles about the FDG PET-CT imaging in inflammatory muscle diseases such as polimyosit, dermatomyositis and metabolic myopathies as in this case.^1,2 In the present case, diagnosis of metabolic myopathy detected on FDG PET-CT imaging performed for investigation of malignancy in a child patient with paraneoplastic syndrome was presented. Rare pediatric metabolic myopathy case FDG PET-CT findings were demonstrated for the first time in the literature. FDG-PET/CT imaging findings were found suspicious for non-malignant skeletal disease and directed the clinician to perform muscle biopsy (Figure 1).

Figure 1 PET/CT MIP (Maximum intensity projection) and axial fusion images demonstrates symmetrical diffuse markedly increased metabolic activity including all the cross-sectional area in skeletal muscle structure.